Anti-IgE therapy

Immunology and Allergy Clinics of North America

Volumn 24, Issue 4 SPEC. ISS., 2004, Pages 551-568

  Brownell, Jaine ^a   Casale, Thomas B ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN RECEPTOR; MONOCLONAL ANTIBODY; OMALIZUMAB;

ALLERGIC RHINITIS; ANAPHYLAXIS; ASTHMA; BLEEDING; BURN; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEVER; FOOD ALLERGY; HEADACHE; HEAT; HUMAN; IMMUNOGLOBULIN PRODUCTION; IMMUNOTHERAPY; INFLAMMATION; INFLUENZA; MALIGNANT NEOPLASTIC DISEASE; MASS; NONHODGKIN LYMPHOMA; PAIN; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; RASH; RESPIRATORY TRACT INFECTION; REVIEW; SERUM SICKNESS; SIDE EFFECT; SINUSITIS; SKIN INDURATION; URTICARIA; VIRUS INFECTION;

EID: 4944255532     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2004.06.002     Document Type: Review

References (51)

1. K. Ishizaka, T. Ishizaka, and W.D. Terry Antigenic structure of gamma-E-globulin and reaginic antibody J Immunol 99 5 1967 849 858
2. D.R. Stanworth Immunochemical mechanisms of immediate-type hypersensitivity reactions Clin Exp Immunol 6 1 1970 1 12
3. American Academy of Allergy, Asthma and Immunology The allergy report 2001 American Academy of Allergy, Asthma and Immunology Milwaukee (WI) 4
4. K.B. Weiss, and S.D. Sullivan The health economics of asthma and rhinitis: I. Assessing the economic impact J Allergy Clin Immunol 107 1 2002 3 8
5. A.S. Bock, B.A. Munoz-Furlong, and H.A. Sampson Fatalities due to anaphylactic reactions to foods J Allergy Clin Immunol 107 1 2002 191 193
6. E.N. Grant, R. Wagner, and K.B. Weiss Observations on emerging patterns of asthma in our society J Allergy Clin Immunol 104 2 Pt 2 1999 s1 s9
7. L.B. Bacharier, and R.S. Geha Molecular mechanisms of IgE regulation J Allergy Clin Immunol 105 2000 S547 S558
8. B. Burrows, F.D. Martinez, M. Halonen, R.A. Barbee, and M.G. Cline Association of asthma with serum IgE levels and skin-test reactivity to allergens N Engl J Med 320 1989 271 277
9. H.C. Oettgen, and R.S. Geha IgE regulation and roles in asthma pathogenesis J Allergy Clin Immunol 107 2001 429 441
10. D. Schmidt, N. Watson, E. Reulmann, H. Magnussen, and K.F. Rabe Serum IgE levels predict human airway reactivity in vitro Clin Exp Allergy 30 2 2000 233 241
11. D.W. MacGlashan, B.S. Bochner, D.C. Adelman, P.M. Jardieu, A. Togias, and J. McKenzie-White Down regulation of FcEεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody J Immunol 158 1997 1438 1445
12. H.C. Oettgen, and R.S. Geha IgE in asthma and atopy: cellular and molecular connections J Clin Invest 104 1999 829 835
13. T.B. Casale, I.L. Bernstein, W.W. Busse, C.F. Laforce, D.G. Tinkelman, and R.R. Stolz Use of anti-IgE humanized monoclonal antibody in ragweed induced allergic rhinitis J Allergy Clin Immunol 100 1 1997 110 121
14. Genentech, Inc. Prescribing information: summary of product characteristics Available at: http://www.xolair.com Accessed January 3, 2003
15. R.L. Shields, W.R. Whether, K. Zioncheck, L. O'Donnell, B. Fendly, and L.G. Presta Inhibition of allergic reactions with antibodies to IgE Int Arch Allergy Immunol 107 1995 308 312
16. L.G. Presta, S.J. Lahr, R.L. Shields, J.P. Porter, C.M. Gorman, and B.M. Fendly Humanization of an antibody directed against IgE J Immunol 151 1993 2623 2632
17. F.C. Breedveld Therapeutic monoclonal antibodies Lancet 355 2000 735 740
18. J. Liu, P. Lester, S. Builder, and S.J. Shire Characterization of complex formation by humanized anti-E monoclonal antibody and monoclonal human IgE Biochemistry 34 33 1995 10474 10482
19. J.A. Fox, T.E. Hotaling, and C. Struble Tissue distribution and complex formation with IgE on anti-IgE Ab after IV administration in cynomolgus monkeys J Pharmacol Exp Ther 279 1996 1000 1008
20. C. Prussin, D.T. Griffith, K.M. Boesel, H. Lin, B. Foster, and T.B. Casale Omalizumab treatment downeregulates dendritic cell FcEεR1 expression J Allergy Clin Immunol 112 6 2003 1147 1154
21. H. Lin, K. Boesel, D. Griffith, C. Prussin, B. Foster, and F.A. Romero Omalizumab rapidly decreases nasal allergic response and FcEεRI on basophils J Allergy Clin Immunol 132 2 2004 297 302
22. J.V. Fahy, H.E. Fleming, H.H. Wong, J.T. Liu, J.Q. Su, and J. Reimann The effect of an anti-IgE monoclonal antibody on the early-and late-phase responses to allergen inhalation in asthmatic subjects Am J Respir Crit Care Med 155 1997 1828 1834
23. A. Togias, J. Corren, and G. Shapiro Anti-IgE treatment reduces skin test (ST) reactivity J Allergy Clin Immunol 101 1998 S171
24. H. Milgrom, R.B. Fick Jr, J.Q. Su, J.D. Reimann, R.K. Bush, and M.L. Watrous Treatment of allergic asthma with monoclonal anti-IgE antibody N Engl J Med 34 1999 1966 1973
25. G. Hochhaus, L. Brookman, H. Fox, C. Johnson, J. Matthews, and S. Ren Pharmacodynamics of omalizumab: implications for optimized dosing strategies and clinical efficacy in the treatment of allergic asthma Curr Med Res Opin 19 6 2003 491 498
26. W. Busse, J. Corren, B.Q. Lanier, M. McAlary, A. Fowler-Taylor, and G.D. Cioppa Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma J Allergy Clin Immunol 108 2 2001 184 190
27. M. Soler, J. Matz, R. Townley, R. Buhl, J. O'Brien, and H. Fox The anti-IgE antibody omalizumab reduces asthma exacerbations and steroid requirement in allergic asthmatics Eur Respir J 18 2 2001 254 261
28. Milgrom H., Berger W., Nayak A., Gupta N., Pollard S., McAlary M., et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108(2):E36. p. 1-10
29. T. Tillinghast, B.Q. Lanier, W. Busse, P. Chervinsky, M. Ashby, and A. Fowler-Taylor Omalizumab significantly increases time to first asthma exacerbation compared with placebo [abstract] Allergy 56 suppl 68 2001 283
30. J. Corren, T.B. Casale, Y. Deniz, and M. Ashby Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma J Allergy Clin Immunol 111 1 2003 87 90
31. E.F. Juniper, G.H. Guyatt, P.J. Ferrie, and L.E. Griffith Measuring quality of life in asthma Am Rev Respir Dis 147 1993 832 838
32. E.F. Juniper, G.H. Guyatt, D.H. Feeny, P.J. Ferrie, L.E. Griffith, and M. Townsend Measuring quality of life in children with asthma Qual Life Res 5 1996 35 46
33. A. Finn, G. Gross, J. van Bavel, T. Lee, H. Windom, and F. Everhard Omalizumab improves asthma-related quality of life in patients with severe allergic asthma J Allergy Clin Immunol 111 2 2003 278 284
34. Lemanske Jr R.F., Nayak A., McAlary M., Everhard F., Fowler-Taylor A., Gupta N. Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics 2002;110(5):e55. p. 1-5
35. B.Q. Lanier, J. Corren, W. Lumry, J. Liu, A. Fowler-Taylor, and N. Gupta Omalizumab is effective in the long-term control of severe allergic asthma Ann Allergy Asthma Immunol 91 2 2003 154 159
36. R. Buhl, M. Soler, J. Matz, R. Townley, J. O'Brien, and O. Noga Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Eur Respir J 20 1 2002 73 78
37. W. Berger, N. Gupta, M. McAlary, and A. Fowler-Taylor Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma Ann Allergy Asthma Immunol 91 2 2003 182 188
38. S. Holgate, J. Bousquet, S. Wenzel, H. Fox, J. Liu, and J. Castellsague Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality Curr Med Res Opin 17 4 2001 233 240
39. S. Holgate, A. Chuchalin, J. Herbert, J. Lotvall, F. Chung, and J. Bousquet Omalizumab, a novel therapy for severe allergic asthma [abstract] Eur Respir J 18 suppl 33 2001 Abst P346
40. J. Bousquet, S. Wenzel, S. Holgate, W. Lumry, P. Freeman, and H. Fox Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma Chest 125 2004 1378 1386
41. S. Holgate, A. Chuchalin, J. Herbert, J. Lotvall, F. Chung, and J. Bousquet Omalizumab improves asthma specific quality of life in patients with severe allergic asthma [abstract] Eur Respir J 18 suppl 33 2001 Abst P348
42. T.B. Casale, J. Condemi, C.F. Laforce, A. Nayak, M. Rowe, and M. Watrons Effect of omalizumab on symptoms of seasonal allergic rhinitis, a randomized controlled trial JAMA 286 23 2001 2956 2967
43. A. Nayak, T.B. Casale, D. Miller, J. Condemi, M. McAlary, and A. Fowler-Taylor Tolerability of retreatment with omalizumab, a recombinant, humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis Allergy Asthma Proc 24 5 2003 323 329
44. E. Adelroth, S. Rak, T. Haahtela, G. Aasand, L. Rosenhall, and O. Zetterstrom Recombinant humanized Mab-E25, an anti-IgE Mab, in birch pollen-induced seasonal allergic rhinitis J Allergy Clin Immunol 106 2000 253 259
45. J. Kuehr, J. Brauburger, S. Zielen, U. Schauer, W. Kamin, and A. Von Berg Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis J Allergy Clin Immunol 109 2002 274 280
46. M.V. Kopp, J. Brauburger, F. Reidinger, D. Beischer, G. Ihorst, and W. Kamin The effect of anti-IgE treatment on in vivo leukotriene release in children with seasonal allergic rhinitis J All Clin Immunol 110 5 2002 728 735
47. P. Chervinsky, T. Casale, R. Townley, I. Tripathy, S. Hedgecock, and A. Fowler-Taylor Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis Ann Allergy Asthma Immunol 91 2 2003 160 167
48. A.M. Vignola, M. Humbert, J. Bousquet, L.P. Boulet, S. Hedgecock, and M. Blogg Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR Allergy 59 2004 709 717
49. W. Schoenwetter, N. Gupta, J. Liu, and A. van As Omalizumab, an anti-immunoglobulin E antibody, is well tolerated in patients with allergic diseases of the airways [abstract] Chest 122 4 Suppl 2002 Abst P118
50. S.G.O. Johansson, N. Gupta, and A. van As Omalizumab, an anti-immunoglobulin E antibody, is not associated with an increased risk of immunological reactions [abstract] Eur Respir J 20 Suppl 38 2002 Abst P741
51. D.M. Leung, H.A. Samson, J.W. Yunginger, A.W. Burks, L.C. Schneider, and C.H. Wortel Effect of anti-IgE therapy in patients with peanut allergy N Engl J Med 348 2003 986 993